Integra LifeSciences reports Q1 adjusted EPS 54c, consensus 40c

Reports Q1 revenue $391.9M, consensus $381.77M. “Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold,” said Stuart Essig, chairman and chief executive officer. “During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix(R) and Durepair(R). We made meaningful progress at our state-of-the-art Braintree manufacturing facility and remain on track to begin production of SurgiMend(R) by the end of June to support a fourth quarter launch. Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full-year commitments to our customers, patients, and shareholders.”